328 related articles for article (PubMed ID: 20851460)
1. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
McCormack S; Ramjee G; Kamali A; Rees H; Crook AM; Gafos M; Jentsch U; Pool R; Chisembele M; Kapiga S; Mutemwa R; Vallely A; Palanee T; Sookrajh Y; Lacey CJ; Darbyshire J; Grosskurth H; Profy A; Nunn A; Hayes R; Weber J
Lancet; 2010 Oct; 376(9749):1329-37. PubMed ID: 20851460
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.
Abdool Karim SS; Richardson BA; Ramjee G; Hoffman IF; Chirenje ZM; Taha T; Kapina M; Maslankowski L; Coletti A; Profy A; Moench TR; Piwowar-Manning E; Mâsse B; Hillier SL; Soto-Torres L;
AIDS; 2011 Apr; 25(7):957-66. PubMed ID: 21330907
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.
Skoler-Karpoff S; Ramjee G; Ahmed K; Altini L; Plagianos MG; Friedland B; Govender S; De Kock A; Cassim N; Palanee T; Dozier G; Maguire R; Lahteenmaki P
Lancet; 2008 Dec; 372(9654):1977-87. PubMed ID: 19059048
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Delany-Moretlwe S; Lombard C; Baron D; Bekker LG; Nkala B; Ahmed K; Sebe M; Brumskine W; Nchabeleng M; Palanee-Philips T; Ntshangase J; Sibiya S; Smith E; Panchia R; Myer L; Schwartz JL; Marzinke M; Morris L; Brown ER; Doncel GF; Gray G; Rees H
Lancet Infect Dis; 2018 Nov; 18(11):1241-1250. PubMed ID: 30507409
[TBL] [Abstract][Full Text] [Related]
5. Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.
Abaasa A; Crook A; Gafos M; Anywaine Z; Levin J; Wandiembe S; Nanoo A; Nunn A; McCormack S; Hayes R; Kamali A
Trials; 2013 Feb; 14():33. PubMed ID: 23374729
[TBL] [Abstract][Full Text] [Related]
6. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.
Kamali A; Byomire H; Muwonge C; Bakobaki J; Rutterford C; Okong P; Profy A; Byaruhanga R; Namukwaya S; McCormack S; Grosskurth H; Nunn AJ; Lacey CJ
Sex Transm Infect; 2010 Jun; 86(3):222-6. PubMed ID: 20444744
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
[TBL] [Abstract][Full Text] [Related]
8. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
9. HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.
Guffey MB; Richardson B; Husnik M; Makanani B; Chilongozi D; Yu E; Ramjee G; Mgodi N; Gomez K; Hillier SL; Karim SA;
Sex Transm Infect; 2014 Aug; 90(5):363-9. PubMed ID: 24898857
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.
Roddy RE; Zekeng L; Ryan KA; Tamoufé U; Weir SS; Wong EL
N Engl J Med; 1998 Aug; 339(8):504-10. PubMed ID: 9709043
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
[TBL] [Abstract][Full Text] [Related]
14. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
15. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.
Padian NS; van der Straten A; Ramjee G; Chipato T; de Bruyn G; Blanchard K; Shiboski S; Montgomery ET; Fancher H; Cheng H; Rosenblum M; van der Laan M; Jewell N; McIntyre J;
Lancet; 2007 Jul; 370(9583):251-261. PubMed ID: 17631387
[TBL] [Abstract][Full Text] [Related]
16. The role of partnership dynamics in determining the acceptability of condoms and microbicides.
Montgomery CM; Lees S; Stadler J; Morar NS; Ssali A; Mwanza B; Mntambo M; Phillip J; Watts C; Pool R
AIDS Care; 2008 Jul; 20(6):733-40. PubMed ID: 18576176
[TBL] [Abstract][Full Text] [Related]
17. "One teabag is better than four": Participants response to the discontinuation of 2% PRO2000/5 microbicide gel in KwaZulu-Natal, South Africa.
Gafos M; Mzimela M; Ndlovu H; Mhlongo N; Hoogland Y; Mutemwa R
PLoS One; 2011 Jan; 6(1):e14577. PubMed ID: 21344002
[TBL] [Abstract][Full Text] [Related]
18. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
Morrow K; Rosen R; Richter L; Emans A; Forbes A; Day J; Morar N; Maslankowski L; Profy AT; Kelly C; Abdool Karim SS; Mayer KH
J Womens Health (Larchmt); 2003 Sep; 12(7):655-66. PubMed ID: 14583106
[TBL] [Abstract][Full Text] [Related]
19. Preventing HIV infection: turning the tide for young women.
McCoy SI; Watts CH; Padian NS
Lancet; 2010 Oct; 376(9749):1281-2. PubMed ID: 20851461
[No Abstract] [Full Text] [Related]
20. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
